source
- Structure’s obesity portfolio impresses on GLP-1 and amylin fronts in dual data dropStructure Therapeutics’ oral GLP-1 candidate aleniglipron showed 72-week efficacy “in line” with Novo Nordisk’s oral Wegovy, BMO Capital Markets wrote in a note to investors. Meanwhile, Structure’s…BioSpace · 46m ago↗ source
- Beyond GLP-1s: Companies eye new obesity drug mechanisms as efficacy plateausThe obesity drug market continues to expand, with GLP-1 therapies growing from about $5.5 billion in 2023 to over $55 billion projected for 2033. These agents are used for weight loss, diabetes and…
- Eli Lilly's Mounjaro gets FDA approval to cut heart attack, stroke risk in type 2 diabetes